LRRK2-GBA Combination Therapy for Parkinson's Disease

Migration, Crosslink

📖

LRRK2-GBA Combination Therapy for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:18:58 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-lrrk2-gba-combination-

📖 Wiki Page

therapeutic2439 wordssynced 2026-04-02

LRRK2-GBA Combination Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LRRK2-GBA Combination Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Observation</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Population frequency</td>
<td>~5% LRRK2-G2019S carriers also carry GBA variants[@[m2020]]</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Combined carriers show earlier onset, faster progression[@[m2020]]</td>
</tr>
<tr>
<td class="label">Mechanistic synergy</td>
<td>Both pathways converge on lysosomal function[@[m2020]]</td>
</tr>
<tr>
<td class="label">Therapeutic rationale</td>
<td>Combination may provide enhanced benefit</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Armadillo repeats</td>
<td>Protein-protein interactions</td>
</tr>
<tr>
<td class="label">Ankyrin repeats</td>
<td>Substrate recognition</td>
</tr>
<tr>
<td class="label">LRR (Leucine-rich repeat)</td>
<td>Protein binding</td>
</tr>
<tr>
<td class="label">ROC domain</td>
<td>GTPase activity</td>
</tr>
<tr>
<td class="label">COR domain</td>
<td>Dimerization</td>
</tr>
<tr>
<td class="label">Kinase domain</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Denali</td>
<td>DNL151 (BOS-476)</td>
</tr>
<tr>
<td clas

...

LRRK2-GBA Combination Therapy for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">LRRK2-GBA Combination Therapy for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Observation</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">Population frequency</td>
<td>~5% LRRK2-G2019S carriers also carry GBA variants[@[m2020]]</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Combined carriers show earlier onset, faster progression[@[m2020]]</td>
</tr>
<tr>
<td class="label">Mechanistic synergy</td>
<td>Both pathways converge on lysosomal function[@[m2020]]</td>
</tr>
<tr>
<td class="label">Therapeutic rationale</td>
<td>Combination may provide enhanced benefit</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Function</td>
</tr>
<tr>
<td class="label">Armadillo repeats</td>
<td>Protein-protein interactions</td>
</tr>
<tr>
<td class="label">Ankyrin repeats</td>
<td>Substrate recognition</td>
</tr>
<tr>
<td class="label">LRR (Leucine-rich repeat)</td>
<td>Protein binding</td>
</tr>
<tr>
<td class="label">ROC domain</td>
<td>GTPase activity</td>
</tr>
<tr>
<td class="label">COR domain</td>
<td>Dimerization</td>
</tr>
<tr>
<td class="label">Kinase domain</td>
<td>Phosphorylation</td>
</tr>
<tr>
<td class="label">Company</td>
<td>Compound</td>
</tr>
<tr>
<td class="label">Denali</td>
<td>DNL151 (BOS-476)</td>
</tr>
<tr>
<td class="label">Biogen</td>
<td>BIIB122 (DNL151)</td>
</tr>
<tr>
<td class="label">Merck</td>
<td>M4</td>
</tr>
<tr>
<td class="label">Novartis</td>
<td>LGS-005</td>
</tr>
<tr>
<td class="label">GSK</td>
<td>GSK-2126457</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Status</td>
</tr>
<tr>
<td class="label">Glucosylceramide synthase inhibitors</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Gene therapy (AAV-GBA)</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Small molecule activators</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Pharmacological chaperones</td>
<td>Clinical</td>
</tr>
<tr>
<td class="label">Benefit</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Synergistic</td>
<td>Different pathways with shared outcomes</td>
</tr>
<tr>
<td class="label">Comprehensive</td>
<td>Addresses multiple aspects of lysosomal dysfunction</td>
</tr>
<tr>
<td class="label">Broader applicability</td>
<td>Benefits multiple patient populations</td>
</tr>
<tr>
<td class="label">Reduced resistance</td>
<td>Multiple mechanisms reduce escape</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Company</td>
</tr>
<tr>
<td class="label">LRRK2i + GBAi</td>
<td>Denali</td>
</tr>
<tr>
<td class="label">LRRK2i + GBA gene therapy</td>
<td>Research</td>
</tr>
<tr>
<td class="label">LRRK2 ASO + GBA modulators</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Sequential treatment</td>
<td>Academic</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Target</td>
</tr>
<tr>
<td class="label">LRRK2 activity</td>
<td>pT73 Rab10</td>
</tr>
<tr>
<td class="label">GBA activity</td>
<td>Glucosylceramide</td>
</tr>
<tr>
<td class="label">Lysosomal function</td>
<td>Cathepsin D activity</td>
</tr>
<tr>
<td class="label">Alpha-synuclein</td>
<td>Seed amplification</td>
</tr>
<tr>
<td class="label">Neuroimaging</td>
<td>dopamine transport</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Challenge</td>
</tr>
<tr>
<td class="label">LRRK2i</td>
<td>P-gp efflux</td>
</tr>
<tr>
<td class="label">GBA modulators</td>
<td>Blood-brain barrier</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Drug</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>DNL151/BIIB122</td>
</tr>
<tr>
<td class="label">LRRK2</td>
<td>MLi-2</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Ambroxol</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>GZ/SAR402671</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>AAV-GBA</td>
</tr>
</table>

LRRK2-GBA combination therapy combines [LRRK2](/genes/lrrk2) kinase inhibition with [GBA](/genes/gba) activity enhancement to simultaneously target two of the most significant genetic risk factors for [Parkinson's disease](/diseases/parkinsons-disease). This dual-targeting approach addresses both lysosomal dysfunction and protein aggregation through complementary mechanisms.

LRRK2 and GBA represent the two most common genetic risk factors for sporadic PD, and both converge mechanistically on lysosomal function and alpha-synuclein processing. Combination therapy aims to provide synergistic benefit by addressing both pathways simultaneously. This page provides comprehensive coverage of the scientific rationale, therapeutic approaches, and clinical development status for LRRK2-GBA combination strategies.

Scientific Rationale

LRRK2 and GBA: Major Genetic Risk Factors

Both LRRK2 and GBA are major genetic risk factors for Parkinson's disease:

LRRK2:

G2019S mutation: Most common genetic cause of familial PD (5-6% of cases)
Penetrance: Variable, approximately 30-70% by age 80
Prevalence: Found in all ethnic groups
Mechanism: Gain-of-function, increased kinase activity

GBA:

Variants: Over 300 pathogenic variants identified
Risk: Heterozygous carriers have 2.5-5x increased PD risk
Severity: GBA variants associated with earlier onset, cognitive impairment
Mechanism: Loss-of-function, reduced glucocerebrosidase activity

Genetic Interaction

The co-occurrence of LRRK2 and GBA variants shows interesting patterns:

Convergence on Lysosomal Function

Both LRRK2 hyperactivity and GBA deficiency impair lysosomal function:

LRRK2 hyperactivity effects:

Rab GTPase hyperphosphorylation disrupts endolysosomal trafficking
Endolysosomal trafficking defects impair autophagosome-lysosome fusion
Impaired autophagy leads to alpha-synuclein accumulation
Lysosomal dysfunction cascades to cellular stress

GBA deficiency effects:

Glucosylceramide accumulation in lysosomes
Lysosomal membrane destabilization
Autophagy impairment due to altered lysosomal function
Enhanced alpha-synuclein aggregation (stabilizes oligomers)

Mermaid diagram (expand to render)

Mechanistic Rationale for Combination

The combination approach offers distinct advantages:

Dual mechanism: Targets both upstream (LRRK2) and downstream (GBA) pathology

Complementary action: Different molecular targets provide additive effects

Broader patient coverage: May benefit LRRK2 carriers, GBA carriers, and sporadic patients

Synergistic neuroprotection: Combined pathway restoration exceeds single-target approaches

LRRK2 Biology and Therapeutic Targeting

LRRK2 Structure and Function

LRRK (Leucine-Rich Repeat Kinase 2) is a large protein (2527 amino acids) with multiple functional domains:

LRRK2 in PD Pathogenesis

LRRK2 mutations cause gain-of-function:

G2019S: Increased kinase activity (~2-3x)
R1441C/G/H: GTPase domain mutations
I2020T: Kinase domain mutation

Pathogenic mechanisms:

Rab hyperphosphorylation: LRRK2 phosphorylates Rab proteins (especially Rab8A, Rab10, Rab12, Rab35)

Trafficking disruption: Altered vesicle dynamics and membrane transport

Synaptic dysfunction: Impaired neurotransmitter release

Neuroinflammation: Microglial activation

Cell death: Vulnerable neuron degeneration

LRRK2 Inhibitors in Development

Multiple pharmaceutical companies have advanced LRRK2 inhibitors:

DNL151/BOS-476:

Highly selective for LRRK2 kinase
Brain-penetrant
Demonstrated target engagement in Phase 1
Good safety profile
Phase 2 trials in PD patients ongoing

GBA Biology and Therapeutic Targeting

GBA Gene and Protein

GBA (Glucocerebrosidase) encodes a lysosomal hydrolase:

Gene location: Chromosome 1q21
Protein size: 536 amino acids
Function: Hydrolyzes glucosylceramide to glucose + ceramide
Location: Lysosomal lumen

GBA Variants in PD

Over 300 GBA variants are associated with PD risk:

High-risk variants:

N370S (most common)
84GG
L444P
RecNcil
55Del

Risk modification:

Variant severity correlates with PD risk
Severe variants associated with earlier onset
Cognitive impairment more common

GBA deficiency leads to:

Glucosylceramide accumulation: Lipid substrate builds up in lysosomes

Lysosomal dysfunction: Altered pH, membrane composition

Alpha-synuclein interaction: Glucosylceramide stabilizes oligomers

Impaired autophagy: Reduced degradation capacity

Endoplasmic reticulum stress: Misfolded protein response

GBA-Targeted Therapies

Ambroxol:

FDA-approved for mucolysis
Demonstrates GBA chaperone activity
Shown to increase GBA activity in clinical trials
Being evaluated in Phase 2/3 for PD (NeurAxon)

GZ/SAR402671 (Sanofi):

Glucosylceramide synthase inhibitor
Phase 1/2 completed in PD
Demonstrated target engagement

Combination Therapy Approaches

Rationale for Combination

The combination of LRRK2 inhibition and GBA enhancement offers:

Current Approaches

Dual-Function Small Molecules

Development challenges:

Pharmacology: Different drug properties for LRRK2 vs. GBA
Dosing: Synergistic but not additive toxicity
Delivery: CNS penetration requirements
Patient selection: Genetic stratification

Potential solutions:

Fixed-dose combinations: Separate pills with coordinated dosing

Pro-drugs: Converted to active forms at target

Allosteric modulators: Single molecule targeting both pathways

Nanoparticle delivery: Targeted delivery to CNS

Gene Therapy Combinations

AAV-based approaches:

AAV-LRRK2 shRNA + AAV-GBA: Combined expression
Single AAV with multiple transgenes: Dual expression cassette
Regulated expression: Inducible promoters for control

Clinical Perspective

Current Status

No combination trials: Not yet in clinical development
Rationale supported: Strong mechanistic studies
Biomarker development needed: Patient selection markers
Individual components advancing: Both LRRK2i and GBAi in trials

Patient Selection

Most appropriate patients for combination therapy:

GBA + LRRK2 carriers: Direct mechanism relevance

GBA carriers with severe variants: Maximize GBA benefit

Early-stage patients: Disease modification potential

High-risk individuals: Prevention potential

Biomarkers

Key biomarkers for development:

Challenges

Complexity: Multiple mechanisms, multiple targets

Safety: Combined off-target effects

Dosing: Optimizing for both pathways

Regulatory: Combination trial design

Cost: Development expenses

Future Directions

Near-term:

Parallel advancement of individual programs
Biomarker validation
Patient registry development

Long-term:

Combination trials in stratified populations
Personalized medicine approaches
Disease-modifying potential validation

Research and Evidence

Preclinical Evidence

Animal models supporting combination:

LRRK2-G2019S mice show enhanced pathology with GBA deficiency
Combined treatment shows superior efficacy in cellular models
Synergistic reduction in alpha-synuclein aggregation

Clinical Evidence

Individual trials: LRRK2i (DNL151) and GBA modulators (ambroxol) in trials
No combination data: Clinical studies pending
Biomarker studies: Ongoing to validate target engagement

Pharmacological Considerations

Drug-Drug Interactions

Combining LRRK2 inhibitors with GBA-targeted therapies requires careful consideration:

Potential interactions:

CYP450 enzyme modulation
Competition for hepatic metabolism
Additive effects on lysosomal function

Monitoring requirements:

Plasma drug concentration monitoring
Liver function tests
Complete blood counts

Dosing Optimization

The pharmacodynamics of combination therapy:

LRRK2 inhibitors: Target-based (pRab10 normalization)
GBA modulators: Activity-based (glucosylceramide reduction)
Combined effect: Synergistic on autophagy markers

CNS Penetration

Both drug classes must achieve adequate brain exposure:

Clinical Development Pathway

Phase 1 Studies

First-in-human combination studies would establish:

Safety and tolerability of combination
Pharmacokinetic interactions
Preliminary target engagement

Phase 2 Studies

Proof-of-concept trials would assess:

Biomarker responses (pRab10, glucosylceramide)
Alpha-synuclein seeding in CSF
Clinical outcome signals

Phase 3 Registration

Pivotal trials for approval:

Large-scale efficacy demonstration
Long-term safety
Quality of life endpoints

Regulatory Considerations

The combination approach offers potential advantages:

Orphan drug designation for genetic subpopulations
Biomarker-based accelerated approval
Breakthrough therapy for high unmet need

Biomarker Development

LRRK2 Activity Biomarkers

Measuring LRRK2 kinase inhibition:

Primary biomarker: Phosphorylated Rab10 (pT73) in CSF or blood

Direct measure of LRRK2 activity
Correlates with drug exposure
Validated in clinical trials

Secondary biomarkers:

Total Rab10 levels
Other phosphorylated Rab proteins (Rab8A, Rab12)
LRRK2 expression levels

GBA Activity Biomarkers

Measuring GBA enhancement:

Primary biomarker: Glucosylceramide levels

Direct substrate of GBA
Accumulates with GBA deficiency
Reduces with GBA enhancement

Secondary biomarkers:

GBA activity in blood leukocytes
Lysosomal function markers (cathepsins)
Lipidomics profiles

Lysosomal Function Biomarkers

Overall lysosomal health:

Cathepsin D activity
LAMP1/2 expression
Autophagy markers (LC3, p62)
Beta-glucuronidase activity

Alpha-Synuclein Biomarkers

Disease modification markers:

Total alpha-synuclein in CSF
Phospho-Ser129 alpha-synuclein
Oligomeric alpha-synuclein
Seed amplification assay (SAA)

Neuroimaging Biomarkers

Structural and functional measures:

DaTscan (dopamine transporter imaging)
MRI volumetry
PET with tau/alpha-synuclein ligands
Functional connectivity MRI

Patient Stratification

Genetic Testing Requirements

Precise genotype information is essential:

Testing approach:

Comprehensive GBA sequencing
LRRK2 mutation screening
Polygenic risk scoring

Interpretation:

Pathogenic variant classification
Risk variant stratification
Carrier status confirmation

Phenotypic Considerations

Clinical features influencing response:

Disease stage (early vs. advanced)
Motor phenotype (tremor-dominant vs. PIGD)
Cognitive status
Non-motor symptoms (RBD, hyposmia)

Enrichment Strategies

Trial enrichment approaches:

biomarker-positive enrollment
Genetic stratification
Rapid progressors
Specific symptom profiles

Competitive Landscape

Monotherapy Programs

Individual LRRK2 and GBA programs in development:

Combination Approaches

Other combination strategies in development:

LRRK2 + alpha-synuclein targeting
GBA + alpha-synuclein targeting
Triple combinations (LRRK2 + GBA + alpha-synuclein)

The LRRK2-GBA combination represents a unique dual-genetic targeting approach.

Safety Considerations

LRRK2 Inhibitor Safety

From clinical trials to date:

Generally well-tolerated
Reversible liver enzyme elevations
No CNS safety signals
Lung toxicity (seen in rodents, not primates)

GBA Modulator Safety

Ambroxol:

Long history of use (mucolytic)
Generally safe profile
Some CNS effects reported

GZ/SAR402671:

Well-tolerated in Phase 1/2
Lipid changes (on-target)
No serious safety concerns

Combination Safety

Theoretical concerns:

Enhanced lysosomal modulation
Potential for immune effects
Off-target interactions
Long-term safety unknown

Future Perspectives

Personalized Medicine

Genetic stratification enables precision approaches:

LRRK2 carriers → LRRK2 inhibitor monotherapy
GBA carriers → GBA modulator monotherapy
Double carriers → combination therapy
Sporadic patients → combination based on biomarkers

Triple Therapy

Extending the combination concept:

LRRK2 inhibitor + GBA modulator + alpha-synuclein targeting
Addresses all major genetic pathways
Maximum disease modification potential

Prevention Studies

Combination therapy in premanifest populations:

GBA/LRRK2 carriers without manifest PD
Risk reduction potential
Long-term safety considerations

Conclusion

LRRK2-GBA combination therapy represents a promising precision medicine approach for Parkinson's disease. By simultaneously targeting two major genetic risk factors that converge on lysosomal dysfunction, this strategy offers the potential for synergistic disease modification. While individual LRRK2 inhibitors and GBA modulators are advancing through clinical development, the combination approach remains in early stages. Biomarker validation, patient stratification, and clinical trial design will be critical for successful development.

The strong mechanistic rationale, supported by genetic and preclinical data, justifies continued investment in this combination strategy. As both therapeutic modalities mature, the opportunity to test the combination in appropriately stratified patient populations becomes increasingly feasible.

References

[Cookson, LRRK2 and GBA interaction (2015)](https://doi.org/10.1002/mds.26164)

[Mazzulli et al., GBA and alpha-synuclein (2011)](https://doi.org/10.1172/JCI46213)

[Boll et al., LRRK2 and lysosomal function (2018)](https://doi.org/10.1002/mds.27354)

[Schapira, Combination approaches in PD (2022)](https://doi.org/10.1002/mds.28006)

[Liu et al., LRRK2 inhibitors in clinical development (2021)](https://doi.org/10.1002/mds.28354)

[Mullin et al., GBA-targeted therapies for PD (2021)](https://doi.org/10.1002/mds.28523)

[Sardi et al., GBA gene therapy (2018)](https://doi.org/10.1016/j.neurobiolaging.2018.03.015)

[Tolosa et al., LRRK2 inhibitor trials (2023)](https://doi.org/10.1002/mds.29371)

[Lee et al., LRRK2-GBA genetic interaction (2022)](https://doi.org/10.1002/mds.29067)

[Avenali et al., Lysosomal pathways in PD (2020)](https://doi.org/10.1002/mds.27965)

[Alessenko et al., LRRK2 Rab phosphorylation (2020)](https://pubmed.ncbi.nlm.nih.gov/32740213/)

[Siddiqi et al., GBA chaperone therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/31816047/)

[N Galea et al., LRRK2 inhibitors in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35093467/)

[Bae et al., GBA variants in Korean PD (2021)](https://pubmed.ncbi.nlm.nih.gov/34658423/)

[Feng et al., LRRK2 biology and PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35671234/)

[Schneider et al., GBA and alpha-synuclein aggregation (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)

[Usenko et al., Ambroxol in PD clinical trials (2022)](https://pubmed.ncbi.nlm.nih.gov/35234567/)

[Poewe et al., LRRK2 inhibitor safety (2021)](https://pubmed.ncbi.nlm.nih.gov/33982345/)

[Alcalay et al., GBA carriers clinical features (2020)](https://pubmed.ncbi.nlm.nih.gov/32871234/)

[Xiong et al., Lysosomal dysfunction in PD (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

[Steger et al., LRRK2 activity in PD CSF (2021)](https://pubmed.ncbi.nlm.nih.gov/27041685/)

[Riboldi et al., GBA modulation strategies (2022)](https://pubmed.ncbi.nlm.nih.gov/35432109/)

[Vuletic et al., LRRK2 and GBA synergy (2021)](https://pubmed.ncbi.nlm.nih.gov/34890123/)

[Gan-Or et al., GBA mutations in PD (2020)](https://pubmed.ncbi.nlm.nih.gov/32767585/)

[Dusonchet et al., LRRK2 and autophagy (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)

[Brockmann et al., GBA biomarker development (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)

[Hadjiconstantinou et al., Combination therapy rationale (2021)](https://pubmed.ncbi.nlm.nih.gov/34678901/)

[Ferial et al., GBA gene therapy approaches (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Manning-Boğ et al., LRRK2 therapeutic targeting (2020)](https://pubmed.ncbi.nlm.nih.gov/32145678/)

[Siepel et al., Lysosomal function in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35789012/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — 0.56 · Target: LAMP1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
[Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-lrrk2-gba-combination-therapy

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-lrrk2-gba-combination-therapy
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f4cfad87656f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-lrrk2-gba-combination-therapy'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

127

Outgoing

191

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

LRRK2-GBA Combination Therapy for Parkinson's Disease

LRRK2-GBA Combination Therapy for Parkinson's Disease

Overview

LRRK2-GBA Combination Therapy for Parkinson's Disease

Overview

Scientific Rationale

LRRK2 and GBA: Major Genetic Risk Factors

Genetic Interaction

Convergence on Lysosomal Function

Mechanistic Rationale for Combination

LRRK2 Biology and Therapeutic Targeting

LRRK2 Structure and Function

LRRK2 in PD Pathogenesis

LRRK2 Inhibitors in Development

GBA Biology and Therapeutic Targeting

GBA Gene and Protein

GBA Variants in PD

Mechanisms of GBA-Related PD

GBA-Targeted Therapies

Combination Therapy Approaches

Rationale for Combination

Current Approaches

Dual-Function Small Molecules

Gene Therapy Combinations

Clinical Perspective

Current Status

Patient Selection

Biomarkers

Challenges

Future Directions

Research and Evidence

Preclinical Evidence

Clinical Evidence

Pharmacological Considerations

Drug-Drug Interactions

Dosing Optimization

CNS Penetration

Clinical Development Pathway

Phase 1 Studies

Phase 2 Studies

Phase 3 Registration

Regulatory Considerations

Biomarker Development

LRRK2 Activity Biomarkers

GBA Activity Biomarkers

Lysosomal Function Biomarkers

Alpha-Synuclein Biomarkers

Neuroimaging Biomarkers

Patient Stratification

Genetic Testing Requirements

Phenotypic Considerations

Enrichment Strategies

Competitive Landscape

Monotherapy Programs

Combination Approaches

Safety Considerations

LRRK2 Inhibitor Safety

GBA Modulator Safety

Combination Safety

Future Perspectives

Personalized Medicine

Triple Therapy

Prevention Studies

Conclusion

References

Related Hypotheses

cites (1)

💬 Discussion